Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Peijia Medical's revenue for the
six
months ended in Dec. 2025 was $51.0 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $100.3 Mil.
Peijia Medical's Revenue per Share for the
six
months ended in Dec. 2025 was $0.08.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.
Warning Sign:
Peijia Medical Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Peijia Medical was 20.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 41.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 62.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 8 years, Peijia Medical's highest 3-Year average Revenue per Share Growth Rate was 130.40% per year. The lowest was 41.70% per year. And the median was 75.35% per year.
Peijia Medical (OTCPK:PEJMF) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Peijia Medical Revenue Related Terms
Peijia Medical Revenue Historical Data
* Premium members only.
The historical data trend for Peijia Medical's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Peijia Medical's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peijia Medical Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Peijia Medical's Revenue distribution charts can be found below:
* The bar in red indicates where Peijia Medical's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $100.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peijia Medical (PEJMF) has a Revenue of $100.3 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Peijia Medical and its competitors.
Is Peijia Medical's Revenue too high?
Peijia Medical's current Revenue is $100.3 Mil. Overall, Peijia Medical has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Peijia Medical's Revenue compare to ABT and SYK?
Peijia Medical's Revenue of $100.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Peijia Medical and its competitors. Peijia Medical's current Revenue is $100.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peijia Medical stock overvalued right now?
Peijia Medical (PEJMF) has a current Revenue of $100.3 Mil. The stock's GF Value™ is $2.78, compared to a current price of $1.39 — trading 50.1% below its estimated fair value. The current Revenue is $100.3 Mil. Peijia Medical's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Peijia Medical (PEJMF), the current Revenue is $100.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Peijia Medical (PEJMF) Overvalued in 2026?
Based on GuruFocus' analysis, Peijia Medical stock appears to be undervalued.
The current stock price of $1.39 is trading 50.1% below its estimated GF Value™ of $2.78.
Key valuation signals for PEJMF:
Revenue: $100.3 Mil
GF Value™: $2.78 vs. price of $1.39 (50.1% below fair value)
No single metric tells the full story. See the PEJMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Peijia Medical Ltdis a provider of inventive medical products and solutions. It focuses on the high-growth interventional procedural medical device market in China. Its products and product candidates target large, fast-growing and under-penetrated markets with high entry barriers, including the transcatheter valve therapeutic medical device market and the neurointerventional procedural medical device market. The Company's product pipeline consists of transcatheter valve therapeutic and neurointerventional products and product candidates spanning three key business segments: Transcatheter Valve Therapeutic Business, Future Technology Business and Neurointerventional Business.
74GF Score
Get the complete analysis for PEJMF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PEJMF has been successfully added to your 
